COVID-19 rapid antigen test

Last updated
COVID-19 rapid antigen test
COVID-19 rapid test.jpg
SARS-CoV-2 rapid tests. Viral antigen detection lateral flow tests
Synonyms COVID-19 rapid antigen detection test (RADT), COVID-19 lateral flow test, COVID-19 lateral flow device, COVID-19 rapid test
PurposeTo diagnose SARS-CoV-2 infections (COVID-19)

COVID-19 rapid antigen tests, also frequently called COVID-19 lateral flow tests , are rapid antigen tests used to detect SARS-COV-2 infection (COVID-19). They are quick to implement with minimal training, offered significant cost advantages, costing a fraction of other forms of COVID-19 testing and give users a result within 5–30 minutes. Rapid antigen tests are used in several countries as part of mass testing or population-wide screening approaches. [1] [2] [3] They are thought to be valuable for identifying individuals who are asymptomatic and could potentially spread the virus to other people, who would otherwise not know they were infected. [4] This differs from other forms of COVID-19 testing, such as PCR, that are generally seen to be a useful test for symptomatic individuals, as they have a higher sensitivity and can more accurately identify cases.


History of COVID-19 rapid test technology development

Covid-19 rapid test being administered in Rwanda Covid-19 rapid test in Rwanda.jpg
Covid-19 rapid test being administered in Rwanda

Rapid tests for COVID-19 emerged from major investment by the United Kingdom's controversial Moonshot program, a £100 billion program to systematically assess, develop and implement new technologies for COVID-19 testing. [5] Rapid tests initially sat within this systematic evaluation pipeline alongside many other putative COVID-19 testing technologies like Lamp, Lampore, point of care PCR, mass spectrometry and sample pooling. However, as evaluations continued, rapid tests emerged as the most successful form of COVID-19 testing within this program to complement existing PCR testing.[ citation needed ]

International guidance for COVID-19 rapid test technology use and development

The early scientific rationale for the potential utility of rapid tests and global direction for rapid test technology development was boosted by interim guidance from the WHO that flagged the potential benefits. [6] The report noted that rapid tests were much easier to implement, and had cost benefits. The WHO recommended their use in outbreaks, for early identification of cases and to monitor disease trends. Later, and subsequent to a rapidly increasing body of studies, this recommendation was expanded by the European Commission. The European Commission recommended the use of rapid test technology for population-wide screening where the proportion of test positivity is high or very high. [7] By January 2021, the European Commission agreed to strengthen their position, advocating much greater use of rapid tests, noting that "should research prove that rapid antigen tests can be conducted by the testee themselves.... self-testing with or without professional guidance could also be considered." [8]

Initial studies

One of the definitive studies for rapid tests was completed by Public Health England, University of Oxford and University of Manchester, and launched by Professor Richard Body and Dr Lennard Lee. The Falcon-C19 study was launched within three days on September 17 2020. The first patient was recruited at the Manchester City Etihad stadium carpark at a new COVID-19 testing research centre. The study rapidly extended to include 14 community research sites across the United Kingdom. The study closed on October 23, having completed testing of 878 individuals. The study was one of the fastest recruiting UK COVID-19 research studies in the country. The study provided definitive evidence that rapid test devices were able to pick up positive results with high accuracy. A total of 4 rapid tests, including the Innova SARS-CoV-2 Antigen Rapid Qualitative Test and the Orientgene COVID-19 IgG/IgM Rapid Test Cassette, were validated in this study, using swab samples from both symptomatic and asymptomatic individuals. [9]

Around the release of the interim analysis of this UK study, the US confirmed that 100 million rapid tests would be purchased from Abbott and shipped across the country to start similar US studies, to complement the University of Oxford initiated studies. [10]

Valuation studies across the world

On 2 November 2020, Slovakia became the first country in the world to initiate country-wide mass testing using rapid tests. Five million rapid tests were performed by 60,000 staff who used the SD Biosensor antigen test and performed swabbing on the population. [11] [12] This then led the European Commission to recommend that rapid tests be used as part of population-wide screening. [1] Two research studies published in early 2021, one by professor Martin Kahanec from Central European University and his coauthors and another one by Martin Pavelka from the London School of Hygiene & Tropical Medicine and his team suggest that the effects of the Autumn wave of rapid antigen mass testing in Slovakia helped to suppress the pandemic in the country, although according to the former study the effect of mass testing on the pandemic was temporary and started to dissipate after about two weeks. [13] [14]

The United Kingdom continued their ongoing rapid test development programme using the Innova rapid test, with increasing urgency as COVID-19 cases increased across Europe. On the 6th of November, the Prime Minister, Boris Johnson, started city-wide screening of Liverpool as part of the accelerated technology evaluation. [15] Further expansion of rapid tests pilots were also launched for many sectors where testing had not been previously available. These included students at Universities who had been particularly hit by outbreaks. This initially started at Durham University, who had the infrastructure and expertise to manage the rapid test programme, [16] but was expanded to the majority of UK universities and enabled the national evacuation-style plan to get students safely home for Christmas. [17] Rapid tests were also implemented within the National Health Service (NHS) for staff to reduce possible transmission to patients, [18] local authorities [19] [20] and care homes to enable visits to visit residents. [21] [22] On 18 November 2020, Wales completed the first whole borough testing at Merthyr Tydfil. [23] [24] At this time, testing was also implemented across schools in the US for students with symptoms [25] and across Portuguese care homes and schools. [26]

Global efforts to step up evaluations of rapid tests were initiated by the World Health Organization (WHO) Emergencies Department who launched a major rapid diagnostic test implementation project on the 10th of November, aided by agreement from the Bill and Melinda Gates Foundation that limited costs for Low and middle-income countries. [27] [28]

Austria started country-wide mass testing on 5 December and ordered seven million tests consisting of the SD Biosensor test and Siemens Clinitest (aka Orientgene). [29] [30]

By the middle of December, there were many studies confirming the efficacy and success of using rapid tests to identify individuals with COVID-19 including studies in the Netherlands, [31] the United Kingdom, [32] and the US. [33] These studies all enabled rapid tests to enter standard national COVID-19 testing strategies. Global piloting of rapid tests was now common place in schools in Canada, [34] travel hubs in Indonesia, [35] and across India. [36]

Concerns about use

Many individuals have raised concerns that the accuracy of rapid tests were not as good as the existing form of COVID-19 testing PCR. Data released from the United Kingdom's City-wide screen in Liverpool illustrated that army operators of the test did obtain the test performance of trained laboratory scientists, [37] following other pilots in India. [38] This caused minor issues within the scientific-psychological community where there was a debate about whether rapid tests might lead to false reassurance and a change in behaviour. However, a shift in thinking about the use of rapid tests was confirmed following a publication from the US. Professor Michael Mina theorised that rapid tests would still be useful as it identified infectious individuals, [39] and potential benefits observed from repeating rapid test and getting a result much quicker than other forms of testing. [40] [41] The United Kingdom's chief clinical medic, Dr Susan Hopkins, also noted that rapid tests provided a means to find “people that...we couldn't otherwise find”. [42]

Noting the ability to identify cases more rapidly, and considering the ensuing escalation in cases in Europe, the European commission met on 11 December and developed a common European framework for “use, validation and mutual recognition of rapid tests”, committing 100 million euros for the purchase of tests from Roche and Abbott. Stella Kyriakides, commissioner for Health and Food Safety said "Rapid antigen tests offer us speed, reliability and quick responses to isolate COVID cases. This is crucial to slow down the spread of the pandemic." [43]

Other individuals have raised concerns about the slow uptake and deployment of rapid tests and potential loss of life that might have occurred as a result. An academic group from Canada noted that half the deaths in care homes in the early part of the pandemic could have been prevented with rapid tests. [44]

Global regulatory approval for use for COVID-19 testing

Following the success of numerous studies across the world to analyse rapid tests from August 2020, rapid tests were approved by regulatory bodies across the world as part of a strategy to use testing as “a new approach to combat the pandemic”. On 16 December, the FDA became the first authority to approve the Abbott rapid test. [45] Subsequent approvals were given for the Ellume COVID-19 home test. [46]

Rapid tests were also approved by Health Canada with their advisor, Professor David Juncter noting “the best rapid tests are highly accurate at detecting contagious individuals“ and Infectious disease specialist Jean Longtin noting "It will allow us to move faster than the virus and find the person's contacts in an hour or two, instead of waiting 24 hours". [47] [48]

The United Kingdom's MHRA confirmed their approval of the Innova rapid test for self-use testing on 23 December. Following the clear global success of this global development of rapid tests, Sir John Bell, Regius professor of medicine at the University of Oxford said “Rapid tests were a central bit of good defence against coronavirus because they were fast, cheap and available for repeat use”. [37] In June 2021, the Food and Drug Administration in the US has issued a Class 1 recall of the Innova LFT's due to their inaccuracy. [49]

Rapid tests as a "return to normal"

Spain became the first country to use rapid tests to facilitate a return-to-normal with Rapid tests being widely available in pharmacies, [50] and a free music concert held in Barcelona for individuals who took a rapid test. [51] A similar approach was taken in Albania to enable music festivals. [52] However, many experts were unsure of this approach believing that “rapid tests are not the solution to restart normal life” [53] but might be used in combination with other vital infection prevention control measures such as wearing appropriate PPE, washing hands regularly and social distancing to allow people to have that vital time with those they love while helping to keep them safer. [54]

New COVID-19 strains

On 22 December 2020, a new, marginally more infectious strain of SARS-CoV-2 was identified in the United Kingdom, VOC-202012/01. The strain rapidly spread across the world. With widespread global use of this form of COVID-19 testing, there was a concern that this variant would render rapid testing obsolete. As part of the UK's accelerated technology evaluation of lateral flow, within 24 hours, Public Health England laboratories were able to confirm rapid test in global development were not affected and they could identify the new variant. This was because rapid test generally targets the nucleocapsid protein and not the spike protein. [55] Some strains however, have recently been identified that do affect some rapid test's sensitivity up to 1000-fold. [56] Fortunately, the frequency of these nucleocapsid mutations (specifically D399N) is still relatively low globally at ~0.02%.

Humanitarian uses for rapid tests

In addition to routine community use, rapid tests have also been utilised as part of humanitarian efforts during the pandemic. Following the flooding in Jakarta in Indonesia on 2 December 2020, rapid tests were made available in flood shelters. [57] Furthermore, following the closure of national borders in Europe following the emergence of the new UK strain just before Christmas 2020, nearly 6,000 lorry drivers were stranded without food, [58] effectively stopping Christmas food deliveries. Rapid tests were deployed by French firefighters within 24 hours at the Channel. Rapid tests enabled lorries to get on the road and complete their deliveries and return to their families for Christmas, demonstrating the potential global utility of having an easily implementable COVID-19 test. [59] [60] Médecins Sans Frontières strongly endorsed the use of rapid tests in lower- and middle-income countries, noting "COVID-19 antigen tests can deliver rapid and actionable results, ensuring timely identification of people infected with the virus at the community level". [61]

America and rapid tests

Having initially invested considerably in rapid test technology development along with the United Kingdom, further evaluation of rapid tests as part of mass testing approaches in the US stalled as a result of the impasse around the $900 billion in COVID-19 relief contained within the 2020 Consolidated Appropriations Act, 2021. The bill was criticised for not specifically ring-fencing investment in rapid tests as a cost-economical and effective form of population-wide testing. [62] Scientists in the US, such as Professor Michael Mina (epidemiologist) of Harvard University, noted that tests were a “very powerful adjunct to everything else that people are already doing” and that "home tests for COVID-19 could slash infection rate". [63] This view was reinforced by Professor William A. Haseltine, also of Harvard, in an article in Forbes magazine proposing "rapid, self-administered testing could stem the ever-surging tide of disease and death" [64] and an article by Professor Annie Sparrow of Mount Sinai, New York proposing "Cheap Mass Testing is Vital for Pandemic Victory" in view of "the emergency of the highly contagious and fast-spreading B117 strain in the UK, and a similar strain from South Africa". [65] Nevertheless, rapid home tests for COVID-19 were publicly available to individuals in January 2021, following the earlier FDA approval. [66] [67] These tests were reimbursed by providers of health insurance in the United States for people with COVID-19 symptoms, or those who have had close contact with an infected person or with someone showing symptoms. [68] An article in the Washington Post proposed that the maximum benefit of rapid tests in the US might not be realised until the "federal government covered testing for asymptomatic people because transmission by those people is such a huge part of the outbreak", as testing these individuals was not covered by health insurance. [67] [69] Following the inauguration of a new president in January 2021, the US restarted investment in rapid test technology development with the publication of presidential executive orders. [70] [71]

Global market value

Following the widespread use of rapid tests across the world, rapid tests have a market value of $15 billion; however, the market is expected to cease from 2024 due to the vaccination of the global population by the end of 2023. [72] In the US, the market for rapid tests was US$3.9 billion with a >20% growth rate in hospitals, clinics, Asia Pacific but also as end-user tests. [73] International market analysts have forecasted that manufacturers of rapid tests will face an ongoing increase in demands as more individuals and countries start to use rapid tests to identify individuals with milder symptoms. [74] A number of commentators and scientists from the US have raised concerns whether the global manufacturing network were able to meet global demand and manufacture the hundreds of millions of tests that would be needed for frequent rapid testing. [75] [76]

Related Research Articles

Lateral flow test Immunochromatographic testing devices

Lateral flow tests (LFTs), also known as lateral flow immunochromatographic assays or rapid tests, are simple devices intended to detect the presence of a target substance in a liquid sample without the need for specialized and costly equipment. These tests are widely used in medical diagnostics for home testing, point of care testing, or laboratory use. For instance, the home pregnancy test is an LFT that detects a specific hormone. These tests are simple, economic and generally show results in around five to 30 minutes. Many lab-based applications increase the sensitivity of simple LFTs by employing additional dedicated equipment.

Rapid antigen test Fast medical lateral flow test

A rapid antigen test (RAT), sometimes called a rapid antigen detection test (RADT), antigen rapid test (ART), or often even just a rapid test, is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. It is commonly used for the detection of SARS-CoV-2, the virus that causes COVID-19. Rapid tests are a type of lateral flow tests that detect antigens, distinguishing it from other medical tests that detect antibodies or nucleic acid, of either laboratory or point-of-care types. Rapid tests generally give a result in 5 to 30 minutes, require minimal training or infrastructure, and have significant cost advantages.

COVID-19 pandemic Ongoing global pandemic of coronavirus disease 2019

The COVID-19 pandemic, also known as the coronavirus pandemic, is an ongoing global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified in the Chinese city of Wuhan in December 2019; a lockdown in Wuhan and other cities in surrounding Hubei failed to contain the outbreak, and it quickly spread to other parts of mainland China and around the world. The World Health Organization (WHO) declared a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. Multiple variants of the virus have emerged and become dominant in many countries since 2021, with the Alpha, Beta, Gamma, Delta and Omicron variants being the most virulent. As of 3 December 2021, more than 264 million cases and 5.24 million deaths have been confirmed, making the pandemic one of the deadliest in history.

Severe acute respiratory syndrome coronavirus 2 Virus that causes COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), is the coronavirus that causes COVID-19, the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus was previously referred to by its provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans. As described by the US National Institutes of Health, it is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.

COVID-19 Contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.

COVID-19 testing Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main branches detect either the presence of the virus or of antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

COVID-19 pandemic in Canada Ongoing COVID-19 viral pandemic in Canada

The COVID-19 pandemic in Canada is part of the ongoing worldwide pandemic of coronavirus disease 2019. It is caused by severe acute respiratory syndrome coronavirus 2. Most cases over the course of the pandemic have been in Ontario, Quebec and Alberta, with Alberta significantly ahead of those two largest provinces for cases per capita. Confirmed cases have been reported in all of Canada's provinces and territories.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID‑19. The COVID‑19 vaccines are widely credited for their role in reducing the severity and death caused by COVID‑19.

The COVID-19 pandemic in Northern Cyprus is part of the ongoing pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2.

COVID-19 drug development Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

Impact of the COVID-19 pandemic on the environment COVID-19 pandemic on environmental issues and Earths climate

As of November 2021, the continuing COVID-19 pandemic had killed over 5 million people. As a result of the severity of the virus, most countries enacted lockdowns to protect people, mitigate the spread, and ensure space in hospitals. These lockdowns disrupted everyday life worldwide, decreasing the level and frequency of human activity and production. Despite the severity of these circumstances, there were clear positive effects on the environment and climate as a result of the slow in activity. As human activity slowed globally, the use of fossil fuels, resource consumption, and waste disposal decreased substantially, generating less air and water pollution in many regions of the world. For example, there was a sharp and lasting decline in planned air travel and vehicle transportation during the COVID-19 pandemic. In China, lockdowns and other measures resulted in a 25% reduction in carbon emissions, 26% decrease in coal consumption, and a 50% reduction in nitrogen oxides emissions. Earth systems scientist Marshall Burke estimated that just two months of pollution reduction likely saved the lives of 77,000 Chinese residents.

Impact of the COVID-19 pandemic on hospitals Consequences of COVID-19 pandemic for hospitals

The COVID-19 pandemic has impacted hospitals around the world. Many hospitals have scaled back or postponed non-emergency care. This has medical consequences for the people served by the hospitals, and it has financial consequences for the hospitals. Health and social systems across the globe are struggling to cope. The situation is especially challenging in humanitarian, fragile and low-income country contexts, where health and social systems are already weak. Health facilities in many places are closing or limiting services. Services to provide sexual and reproductive health care risk being sidelined, which will lead to higher maternal mortality and morbidity. The pandemic also resulted in the imposition of COVID-19 vaccine mandates in places such as California and New York for all public workers, including hospital staff.

Viral disease testing is the use of a variety of testing techniques for a variety of purposes, including diagnosing conditions, assessing immunity and understanding disease prevalence. The primary approaches include DNA/RNA tests, serological tests and antigen tests.

Coronavirus breathalyzer Diagnostic medical device

A coronavirus breathalyzer is a diagnostic medical device enabling the user to test with 90% or greater accuracy the presence of severe acute respiratory syndrome coronavirus 2 in an exhaled breath. As of the first half of 2020, the idea of a practical coronavirus breathalyzer was concomitantly developed by unrelated research groups in the Singapore, United States, The Netherlands, Finland, Germany, Israel, England, Australia, Indonesia, Canada, Poland and United Kingdom.

Operation Moonshot is a UK government programme to introduce same day mass testing for COVID-19 in England as a way of enabling large gatherings of people to take place in that country while maintaining control over the virus. According to the British Medical Journal, the programme aims to deliver 10 million tests per day by 2021.

COVID-19 Genomics UK Consortium

The COVID-19 Genomics UK Consortium (COG-UK) is a group of public health agencies and academic institutions in the United Kingdom created in April 2020 to collect, sequence and analyse genomes of SARS-CoV-2 as part of COVID-19 pandemic response. The consortium comprises the UK's four public health agencies, National Health Service organisations, academic partners and the Wellcome Sanger Institute. The consortium is known for first identifying the SARS-CoV-2 Alpha variant in November 2020. As of January 2021, 45% of all SARS-CoV-2 sequences uploaded to the GISAID sequencing database originated from COG-UK.

Michael Joseph Mina is an American epidemiologist, immunologist and physician who is an Assistant Professor of Epidemiology & Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and Assistant Professor of Pathology at Brigham and Women's Hospital, Harvard Medical School. He has at least 80 scientific publications. The most cited ones are related to immunology or epidemiology. He is notable for his promotion of using rapid antigen tests to halt or slow the COVID-19 pandemic.

Development of COVID-19 tests

The development of COVID-19 tests was a major public health priority during the early months of the COVID-19 pandemic.

Various kinds of software have been developed and used for mitigating the COVID-19 pandemic. These include mobile apps for contact tracing and notifications about infection risks, digital passports verifying one's vaccination status, software for enabling – or improving the effectiveness of – lockdowns and social distancing in general, Web software for the creation of related information services, and software for the research and development for COVID-19 mitigation.

United Kingdom responses to the COVID-19 pandemic Actions by the United Kingdom regarding the COVID-19 pandemic

The United Kingdom's response to the COVID-19 pandemic with consists of various measures by the national health services community; the British and devolved governments; the military; and the research sector.


  1. 1 2 "Press corner". European Commission – European Commission. Retrieved 2021-03-20.
  2. "Slovakia carries out Covid mass testing of two-thirds of population". The Guardian. Agence France-Presse. 2 November 2020. ISSN   0261-3077.
  3. Peter Littlejohns (6 November 2020). "The UK is trialling lateral flow testing for Covid-19 – how does it work?". NS Medical Devices.
  4. Guglielmi G (September 2020). "Fast coronavirus tests: what they can and can't do". Nature. 585 (7826): 496–498. Bibcode:2020Natur.585..496G. doi: 10.1038/d41586-020-02661-2 . PMID   32939084.
  5. Iacobucci G, Coombes R (September 2020). "Covid-19: Government plans to spend £100bn on expanding testing to 10 million a day". BMJ. 370: m3520. doi: 10.1136/bmj.m3520 . PMID   32907851.
  6. "Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays". Word Health Organization. Retrieved 20 March 2021.
  7. "Coronavirus: Commission puts forward rules on rapid antigen tests and secures 20 million tests for Member States". European Council. Retrieved 20 March 2021.
  8. "Council agrees on strengthening the use of rapid antigen tests and on the mutual recognition of COVID-19 test results". Council of the EU. Retrieved 20 March 2021.
  9. "Oxford University and PHE confirm lateral flow tests show high specificity and are effective at identifying most individuals who are infectious - University of Oxford". Retrieved 2020-12-27.
  10. "The U.S. is conducting millions more rapid coronavirus tests, but are results reported?". Global News. Retrieved 2020-12-27.
  11. Mahase E (December 2020). "Covid-19: Mass testing in Slovakia may have helped cut infections". BMJ. 371: m4761. doi: 10.1136/bmj.m4761 . PMID   33293348.
  12. Agence France-Presse (2020-11-02). "Slovakia carries out Covid mass testing of two-thirds of population". The Guardian. ISSN   0261-3077 . Retrieved 2020-12-27.
  13. Kahanec M, Laffers L, Schmidpeter B (June 2021). "The Impact of Repeated Mass Antigen Testing for COVID-19 on the Prevalence of the Disease". Journal of Population Economics. 34 (4): 1105–1140. doi: 10.1007/s00148-021-00856-z . PMC   8241209 . PMID   34219976.
  14. Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M, Jarčuška P, et al. (May 2021). "The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia". Science. 372 (6542): 635–641. doi: 10.1126/science.abf9648 . PMC   8139426 . PMID   33758017.
  15. Boseley S, Elgot J (2020-11-02). "Liverpool to pioneer UK's first attempt at mass Covid testing". The Guardian. ISSN   0261-3077 . Retrieved 2020-12-27.
  16. Sigsworth T (2020-11-19). "Covid-19 updates: University's lateral flow tests available to book from tomorrow". Palatinate. Retrieved 2020-12-27.
  17. "Covid-19: Universities to oversee student exodus for Christmas". BBC News. 2020-11-11. Retrieved 2020-12-27.
  18. Serle J (9 November 2020). "NHS staff to get twice-weekly home covid tests with immediate effect". Health Service Journal. Retrieved 2020-12-27.
  19. "More rapid COVID-19 tests to be rolled out across England". GOV.UK. 2020-11-09. Retrieved 2020-12-27.
  20. "Roll out of lateral flow tests to local authorities". GOV.UK. 2020-11-13. Retrieved 2020-12-27.
  21. "COVID-19: Care home residents allowed to see family after rapid tests rolled out – 'it was very emotional'". Sky News. 2020-12-25. Retrieved 2020-12-27.
  22. "£149 million to support increased care home testing". GOV.UK. Retrieved 2020-12-27.
  23. "Mass Testing in Merthyr Tydfil to continue until Friday". 2020-12-14. Retrieved 2020-12-27.
  24. Wightwick A (2020-12-10). "Results of mass coronavirus testing in Merthyr schools released". WalesOnline. Retrieved 2020-12-27.
  25. Ohm R (2020-12-21). "Dozens of Maine schools now using COVID rapid tests for students and staff". Press Herald. Retrieved 2020-12-27.
  26. Donn N (2020-10-27). "Portugal rolls out 'rapid tests' to help stem outbreaks in schools and OAP homes". Portugal Resident. Retrieved 2020-12-27.
  27. "SARS-CoV-2 Antigen detecting rapid diagnostic test implementation projects". 2020-11-10. Retrieved 2020-12-27.
  28. "Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries". 2020-09-28. Retrieved 2020-12-27.
  29. "COVID-19 Mass Testing in Austria: All Details". | Vienna International News. Retrieved 2020-12-27.
  30. "'20,000 a day': How mass testing is working in Austria". 2020-12-07. Retrieved 2020-12-27.
  31. Gremmels H, Winkel BM, Schuurman R, Rosingh A, Rigter NA, Rodriguez O, et al. (January 2021). "Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection". EClinicalMedicine. 31: 100677. doi: 10.1016/j.eclinm.2020.100677 . PMC   7832943 . PMID   33521610.
  32. Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, et al. (November 2020). "A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay". Journal of Clinical Virology. 132: 104645. doi:10.1016/j.jcv.2020.104645. PMC   7493757 . PMID   32961429.
  33. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, et al. (July 2020). "Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution". Journal of Clinical Microbiology. 58 (8). doi: 10.1128/JCM.01136-20 . PMC   7383552 . PMID   32471894.
  34. "Rapid COVID-19 Testing Expands to Include Vulnerable Populations in Alberta". 2020-12-23. Retrieved 2020-12-27.
  35. CoconutsBali (2020-12-22). "Passengers form long queues to take antigen rapid tests in Bali's Ngurah Rai Airport | Coconuts Bali". Coconuts. Retrieved 2020-12-27.
  36. Pinto R, Iyer M (Jun 28, 2020). "Mumbai: As 15-minutes rapid tests start this week, spike in cases expected". Mumbai News. The Times of India. Retrieved 2020-12-27.
  37. 1 2 Topping A (2020-12-23). "Scientists in Liverpool mass Covid testing trial defend rapid tests". The Guardian. ISSN   0261-3077 . Retrieved 2020-12-27.
  38. Saxena R (2020-08-17). "Why India's rapid antigen tests for coronavirus are like 'flipping a coin'". ThePrint. Retrieved 2020-12-27.
  39. Mina MJ, Parker R, Larremore DB (November 2020). "Rethinking Covid-19 Test Sensitivity – A Strategy for Containment". The New England Journal of Medicine. 383 (22): e120. doi: 10.1056/NEJMp2025631 . PMID   32997903.
  40. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. (January 2021). "Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening". Science Advances. 7 (1): eabd5393. Bibcode:2021SciA....7.5393L. doi: 10.1126/sciadv.abd5393 . PMC   7775777 . PMID   33219112.
  41. Shirazi S, Stanford CM, Cooper LF (May 2021). "Testing for COVID-19 in dental offices: mechanism of action, application and interpretation of laboratory and point-of-care screening tests". The Journal of the American Dental Association. 152 (7): 514–525.e8. doi:10.1016/j.adaj.2021.04.019. ISSN   0002-8177. PMC   8096195 . PMID   34176567.
  42. "Negative result in rapid Covid test is not green light to abandon social distancing, top medic warns". The Independent. 2020-12-05. Retrieved 2020-12-27.
  43. "Press corner". European Commission – European Commission. Retrieved 2020-12-27.
  44. "Rapid tests could have prevented half of B.C. care home deaths in 2020, modelling suggests". CTVNews. 29 January 2021. Retrieved 2021-03-20.
  45. Office of the Commissioner (2020-12-17). "Coronavirus (COVID-19) Update: FDA Issues New Authorization for the BinaxNOW COVID-19 Ag Card Home Test". FDA. Retrieved 2020-12-27.
  46. Courage KH (2020-12-18). "Rapid at-home Covid-19 tests are finally here. Here's how they could help end the pandemic". Vox. Retrieved 2020-12-27.
  47. "Rapid test very reliable when used on symptomatic patients, Quebec scientists find | CBC News". CBC. Retrieved 2020-12-27.
  48. Rapid Test & Trace Canada (2020-12-17). "Rapid Test & Trace Canada raises awareness about the benefits of rapid testing and tracing". GlobeNewswire News Room. Retrieved 2020-12-27.
  49. Health, Center for Devices and Radiological (2021-06-10). "Stop Using Innova SARS-CoV-2 Antigen Rapid Qualitative Test: FDA Safety Communication". FDA.
  50. Glenn A (2020-12-07). "Pharmacies in Spain to Roll out Rapid Tests for COVID-19". Euro Weekly News Spain. Retrieved 2020-12-27.
  51. Dorn S (2020-12-13). "Barcelona hosts concert for 500 residents in COVID rapid-test experiment". New York Post. Retrieved 2020-12-27.
  52. "Albanian government has approved rapid Covid testing for Unum Festival 2021". Crack Magazine. 2020-12-02. Retrieved 2020-12-27.
  53. "Rapid tests are not the solution to restart normal life, expert says". The Brussels Times. 2020-12-22. Retrieved 2020-12-27.
  54. "Lateral flow testing – new rapid tests to detect COVID-19 – Public health matters". Retrieved 2020-12-27.
  55. "Rapid evaluation confirms lateral flow devices effective in detecting new COVID-19 variant". GOV.UK. Retrieved 2020-12-27.
  56. Bourassa, Lori; Perchetti, Garrett A.; Phung, Quynh; Lin, Michelle J.; Mills, Margaret G.; Roychoudhury, Pavitra; Harmon, Kimberly G.; Reed, Jonathan C.; Greninger, Alexander L. (2021-05-05). "A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance". medRxiv: 2021.05.05.21256527. doi:10.1101/2021.05.05.21256527. S2CID   233739399.
  57. "North Jakarta to provide rapid tests for people in flood shelters". The Jakarta Post. Retrieved 2020-12-27.
  58. "Covid-19: Charities send food to stranded truckers". BBC News. 2020-12-23. Retrieved 2020-12-27.
  59. Rawlinson K, Halliday J (2020-12-24). "Army to take over Covid testing for hauliers trapped near Dover". The Guardian. ISSN   0261-3077 . Retrieved 2020-12-27.
  60. "COVID-19: Raw anger among lorry drivers in Dover as coronavirus testing fails to ease tensions". Sky News. Retrieved 2020-12-27.
  61. "COVID-19 diagnostics: MSF welcomes more affordable rapid tests for lower- and middle-income countries – World". ReliefWeb. Retrieved 2021-03-20.
  62. Dickerson M. "9 Things You Need to Know About the $1.4 Trillion Fiscal Year 2021 Omnibus and $900 Billion COVID-19 Package". The Heritage Foundation. Retrieved 2021-03-20.
  63. Allen V (2020-12-11). "How Rapid-Result, at-Home COVID-19 Tests Could Slash Infection Rate". The Daily Signal. Retrieved 2021-03-20.
  64. Haseltine WA. "Even With A Vaccine, We Still Need Rapid Tests To End Covid-19". Forbes. Retrieved 2021-03-20.
  65. Sparrow A. "Cheap Mass Testing Is Vital for Pandemic Victory". Foreign Policy. Retrieved 2021-03-20.
  66. Courage KH (2020-12-18). "Rapid at-home Covid-19 tests are finally here. Here's how they could help end the pandemic". Vox. Retrieved 2021-03-20.
  67. 1 2 Wan, William (December 16, 2020). "How do home tests for coronavirus work? Where can I get one?". The Washington Post .
  68. Appleby, Julie; Kaiser Health News (18 June 2020). "Is your COVID test covered? The answer is up for interpretation". NBC News. Retrieved 15 September 2021.
  69. HRSA Staff. "FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration". Official web site of the U.S. Health Resources & Services Administration. Retrieved 15 September 2021.
  70. "Combating COVID-19". The White House. Retrieved 2021-03-20.
  71. "Biden executive orders address COVID-19, other health care issues". Roll Call. 2021-01-21. Retrieved 2021-03-20.
  72. "Global COVID 19 Rapid Test Kits Market Size, Share, Trends, Strategies". Retrieved 2020-12-27.
  73. Reports and Data (2020-04-28). "Rapid Test Kit Market For COVID-19 To Reach USD 3.91 Billion By 2027 | Reports and Data". GlobeNewswire News Room. Retrieved 2020-12-27.
  74. The Business Research Company (2020-09-03). "COVID-19 Rapid Test Kits Manufacturing To Increase Due To Testing Of People With Mild Symptoms". GlobeNewswire News Room. Retrieved 2020-12-27.
  75. Rubin R (November 2020). "The Challenges of Expanding Rapid Tests to Curb COVID-19". JAMA. 324 (18): 1813–1815. doi: 10.1001/jama.2020.21106 . PMID   33084882.
  76. "Huge demand for COVID-19 rapid antigen testing may face manufacturing constraints". Modern Healthcare. 2020-10-08. Retrieved 2020-12-27.